Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Fall;14(4):377-380.
doi: 10.1097/ICB.0000000000000717.

EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS

Caroline Bormann  1 , Bianca C Apitzsch  2 , Anke Habermann  1 , Ute Hammer  1 , Thomas Hammer  1   3
Affiliations
Clinical Trial

EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS

Caroline Bormann et al. Retin Cases Brief Rep. 2020 Fall.

Abstract

Purpose: To assess the efficacy of ocriplasmin in patients with vitreomacular traction (VMT) syndrome <1,500 μm with or without a full-thickness macular holes of <400 μm.

Methods: In this study, a retrospective analysis of 10 eyes of 10 patients with VMT who were treated with ocriplasmin between December 2014 and January 2016 was performed. Ocriplasmin 0.125 mg was injected only once in all cases. Outcome measures included the detachment of VMT, best-corrected visual acuity, the evaluation of optical coherence tomography, including the closure of full-thickness macular holes, and the reduction of macular edema (if present) and the decrease of metamorphopsia if present.

Results: Ten patients (7 women and 3 men) with an average age of 75.1 years (range, 63-84 years) were treated with ocriplasmin with a follow-up period of 8 weeks. All patients were treated for VMT syndrome, and 5 patients (50.0%) showed an additional macular hole. An absolute detachment of VMT was seen in 3 patients (30.0%) and partially in 4 patients (40.0%). In three of the five patients, a complete closure of the full-thickness macular holes was seen. The two other patients needed an additional pars plana vitrectomy as a result of the persistent macular hole. An improvement of visual acuity was seen in 6 out of 10 patients (60.0%), a reduction of macular edema in 8 out of 9 patients (88.9%), and a decrease of metamorphopsia in 6 out of 7 patients (85.7%).

Conclusion: In this retrospective analysis, the treatment with ocriplasmin showed a resolution of VMT in 7 of 10 patients (70.0%) after a follow-up period of 8 weeks.

PubMed Disclaimer

References

    1. Greven MA, Garg S, Chiu B, et al. Vitrectomy afterocriplasmin for vitreomacular adhesion or macular hole (VAVOOM) study. Br J Ophthalmol 2016;100:1211–1215.
    1. Flynn HW Jr, Relhan N. The Charles Schepens lecture: management options for vitreomacular traction: use an individualized approach. Ophthalmol Retina 2017;1:3–7.
    1. Dugel PU, Tolentino M, Feiner L, et al. Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial. Ophthalmology 2016;123:2232–2247.
    1. Liang IC, Wang K, Chien HW, et al. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment. Indian J Ophthalmol 2016;64:222–224.
    1. Chatziralli I, Theodossiadis G, Parikakis E, et al. Real-life experience after intravitrealocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol 2016;254:223–233.

Publication types

MeSH terms